| 6.1 1.65 (37.08%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.07 | 1-year : | 8.68 |
| Resists | First : | 6.05 | Second : | 7.44 |
| Pivot price | 5.63  |
|||
| Supports | First : | 3.8 | Second : | 3.16 |
| MAs | MA(5) : | 5.63 |
MA(20) : | 5.81 |
| MA(100) : | 5.7  |
MA(250) : | 2.97 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 17.9 |
D(3) : | 28.5 |
| RSI | RSI(14): 44.3 |
|||
| 52-week | High : | 14.1 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BSGM ] has closed above bottom band by 5.1%. Bollinger Bands are 60.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.7 - 5.72 | 5.72 - 5.75 |
| Low: | 4.89 - 4.92 | 4.92 - 4.95 |
| Close: | 4.95 - 5 | 5 - 5.05 |
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Fri, 12 Sep 2025
BioSig Technologies Rebrands to Streamex Corp. - The Globe and Mail
Wed, 10 Sep 2025
BioSig Technologies, Inc. Rebrands as Streamex Corp., Trading Symbol Changes to STEX - Quiver Quantitative
Wed, 10 Sep 2025
Major Nasdaq Rebrand: BioSig Technologies Transforms to Streamex Corp with New Trading Symbol STEX - Stock Titan
Wed, 13 Aug 2025
BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering - GlobeNewswire
Fri, 25 Jul 2025
BioSig Technologies and Streamex: Pioneering Real-World Asset Tokenization in the U.S. Market - ETF.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 2.553e+007 (%) |
| Held by Institutions | 28.7 (%) |
| Shares Short | 1,350 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.684e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -211 % |
| Return on Assets (ttm) | 407.6 % |
| Return on Equity (ttm) | -30.5 % |
| Qtrly Rev. Growth | 13000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 7142.85 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -75.99 |
| Dividend | 0 |
| Forward Dividend | 1.75e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|